Long-term effectiveness of levodopa-carbidopa intestinal gel in 177 Spanish patients with advanced Parkinson's disease
To assess long-term effectiveness and tolerability of levodopa-carbidopa intestinal gel (LCIG) in Spanish patients with advanced Parkinson's disease. This was an observational, multicenter, cross-sectional, retrospective study. Data of 177 patients were analyzed. LCIG treatment led to a reducti...
Gespeichert in:
| Veröffentlicht in: | Neurodegenerative disease management 2016-08, Vol.6 (4), p.289-298 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 298 |
|---|---|
| container_issue | 4 |
| container_start_page | 289 |
| container_title | Neurodegenerative disease management |
| container_volume | 6 |
| creator | Valldeoriola, Francesc Grandas, Francisco Santos-García, Diego Regidor, Ignacio Catalán, María José Arbelo, José Matías Puente, Víctor Mir, Pablo Parra, Juan Carlos |
| description | To assess long-term effectiveness and tolerability of levodopa-carbidopa intestinal gel (LCIG) in Spanish patients with advanced Parkinson's disease.
This was an observational, multicenter, cross-sectional, retrospective study.
Data of 177 patients were analyzed. LCIG treatment led to a reduction in the percentage of daily 'off' time (16.2 vs 47.6% before LCIG), an increase in the percentage of daily 'on' time without disabling dyskinesia (55.6 vs 21.6%). Most patients experienced improvements in freezing of gait, tremor, dizziness, fatigue or flat mood. Adverse events related to levodopa, gastrostomy and technical issues were reported in 36.2, 42.4 and 43.5% of patients, respectively.
This study confirms the long-term effectiveness and safety profile of LCIG in patients with advanced Parkinson's disease. |
| doi_str_mv | 10.2217/nmt-2016-0021 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2341594412</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2341594412</sourcerecordid><originalsourceid>FETCH-LOGICAL-c371t-8de77a445720c4f55519ee75036d5d7e61013cfbd1ca554b4c33de43a4b17b273</originalsourceid><addsrcrecordid>eNp1kE1LxDAQhoMoKusevUrAg6dqPht7FPELFhTUc0iTqUZ305qkFf-9WVa9OZfMhGdehgehQ0pOGaPqLKxyxQitK0IY3UL7VMnz8sHZ9l_PxB6ap_RGStWE1bzZRXtMCUFoQ_bRtOjDS5UhrjB0HdjsJwiQEu47vISpd_1gKmti69cd9iFDyj6YJX6BZRkxVQo_Dib49IoHkz2EnPCnz6_YuMkECw4_mPjuQ-rDScLOJzAJDtBOZ5YJ5j_vDD1fXz1d3laL-5u7y4tFZbmiuTp3oJQRQipGrOiklLQBUJLw2kmnoKaEctu1jlojpWiF5dyB4Ea0VLVM8Rk63uQOsf8Yy-n6rR9jOT9pxgWVjRCUFaraUDb2KUXo9BD9ysQvTYlei9ZFtF6L1mvRhT_6SR3bFbg_-ldrAZoN0I15jJBs0WJBb6ay4a0P8E_4N_CQjQY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2341594412</pqid></control><display><type>article</type><title>Long-term effectiveness of levodopa-carbidopa intestinal gel in 177 Spanish patients with advanced Parkinson's disease</title><source>MEDLINE</source><source>PubMed Central</source><creator>Valldeoriola, Francesc ; Grandas, Francisco ; Santos-García, Diego ; Regidor, Ignacio ; Catalán, María José ; Arbelo, José Matías ; Puente, Víctor ; Mir, Pablo ; Parra, Juan Carlos</creator><creatorcontrib>Valldeoriola, Francesc ; Grandas, Francisco ; Santos-García, Diego ; Regidor, Ignacio ; Catalán, María José ; Arbelo, José Matías ; Puente, Víctor ; Mir, Pablo ; Parra, Juan Carlos</creatorcontrib><description>To assess long-term effectiveness and tolerability of levodopa-carbidopa intestinal gel (LCIG) in Spanish patients with advanced Parkinson's disease.
This was an observational, multicenter, cross-sectional, retrospective study.
Data of 177 patients were analyzed. LCIG treatment led to a reduction in the percentage of daily 'off' time (16.2 vs 47.6% before LCIG), an increase in the percentage of daily 'on' time without disabling dyskinesia (55.6 vs 21.6%). Most patients experienced improvements in freezing of gait, tremor, dizziness, fatigue or flat mood. Adverse events related to levodopa, gastrostomy and technical issues were reported in 36.2, 42.4 and 43.5% of patients, respectively.
This study confirms the long-term effectiveness and safety profile of LCIG in patients with advanced Parkinson's disease.</description><identifier>ISSN: 1758-2024</identifier><identifier>EISSN: 1758-2032</identifier><identifier>DOI: 10.2217/nmt-2016-0021</identifier><identifier>PMID: 27440190</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>'off' time ; Aged ; Antiparkinson Agents - therapeutic use ; Carbidopa - therapeutic use ; Cross-Sectional Studies ; Dopamine ; Drug Combinations ; dyskinesia ; Enrollments ; Family medical history ; Female ; Gels - therapeutic use ; Humans ; Intestines - physiology ; Intravenous therapy ; Levodopa - therapeutic use ; levodopa-carbidopa intestinal gel ; Logistics ; Longitudinal Studies ; Male ; Middle Aged ; Motor Activity - drug effects ; nonmotor symptoms ; Ostomy ; Parkinson Disease - drug therapy ; Parkinson Disease - physiopathology ; Parkinson's disease ; Patients ; Performance evaluation ; Quality of life ; Regression analysis ; Retrospective Studies ; Severity of Illness Index ; Spain ; Standard deviation ; Studies</subject><ispartof>Neurodegenerative disease management, 2016-08, Vol.6 (4), p.289-298</ispartof><rights>Future Medicine Ltd</rights><rights>Copyright Future Medicine Ltd Aug 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c371t-8de77a445720c4f55519ee75036d5d7e61013cfbd1ca554b4c33de43a4b17b273</citedby><cites>FETCH-LOGICAL-c371t-8de77a445720c4f55519ee75036d5d7e61013cfbd1ca554b4c33de43a4b17b273</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27929,27930</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27440190$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Valldeoriola, Francesc</creatorcontrib><creatorcontrib>Grandas, Francisco</creatorcontrib><creatorcontrib>Santos-García, Diego</creatorcontrib><creatorcontrib>Regidor, Ignacio</creatorcontrib><creatorcontrib>Catalán, María José</creatorcontrib><creatorcontrib>Arbelo, José Matías</creatorcontrib><creatorcontrib>Puente, Víctor</creatorcontrib><creatorcontrib>Mir, Pablo</creatorcontrib><creatorcontrib>Parra, Juan Carlos</creatorcontrib><title>Long-term effectiveness of levodopa-carbidopa intestinal gel in 177 Spanish patients with advanced Parkinson's disease</title><title>Neurodegenerative disease management</title><addtitle>Neurodegener Dis Manag</addtitle><description>To assess long-term effectiveness and tolerability of levodopa-carbidopa intestinal gel (LCIG) in Spanish patients with advanced Parkinson's disease.
This was an observational, multicenter, cross-sectional, retrospective study.
Data of 177 patients were analyzed. LCIG treatment led to a reduction in the percentage of daily 'off' time (16.2 vs 47.6% before LCIG), an increase in the percentage of daily 'on' time without disabling dyskinesia (55.6 vs 21.6%). Most patients experienced improvements in freezing of gait, tremor, dizziness, fatigue or flat mood. Adverse events related to levodopa, gastrostomy and technical issues were reported in 36.2, 42.4 and 43.5% of patients, respectively.
This study confirms the long-term effectiveness and safety profile of LCIG in patients with advanced Parkinson's disease.</description><subject>'off' time</subject><subject>Aged</subject><subject>Antiparkinson Agents - therapeutic use</subject><subject>Carbidopa - therapeutic use</subject><subject>Cross-Sectional Studies</subject><subject>Dopamine</subject><subject>Drug Combinations</subject><subject>dyskinesia</subject><subject>Enrollments</subject><subject>Family medical history</subject><subject>Female</subject><subject>Gels - therapeutic use</subject><subject>Humans</subject><subject>Intestines - physiology</subject><subject>Intravenous therapy</subject><subject>Levodopa - therapeutic use</subject><subject>levodopa-carbidopa intestinal gel</subject><subject>Logistics</subject><subject>Longitudinal Studies</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Motor Activity - drug effects</subject><subject>nonmotor symptoms</subject><subject>Ostomy</subject><subject>Parkinson Disease - drug therapy</subject><subject>Parkinson Disease - physiopathology</subject><subject>Parkinson's disease</subject><subject>Patients</subject><subject>Performance evaluation</subject><subject>Quality of life</subject><subject>Regression analysis</subject><subject>Retrospective Studies</subject><subject>Severity of Illness Index</subject><subject>Spain</subject><subject>Standard deviation</subject><subject>Studies</subject><issn>1758-2024</issn><issn>1758-2032</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kE1LxDAQhoMoKusevUrAg6dqPht7FPELFhTUc0iTqUZ305qkFf-9WVa9OZfMhGdehgehQ0pOGaPqLKxyxQitK0IY3UL7VMnz8sHZ9l_PxB6ap_RGStWE1bzZRXtMCUFoQ_bRtOjDS5UhrjB0HdjsJwiQEu47vISpd_1gKmti69cd9iFDyj6YJX6BZRkxVQo_Dib49IoHkz2EnPCnz6_YuMkECw4_mPjuQ-rDScLOJzAJDtBOZ5YJ5j_vDD1fXz1d3laL-5u7y4tFZbmiuTp3oJQRQipGrOiklLQBUJLw2kmnoKaEctu1jlojpWiF5dyB4Ea0VLVM8Rk63uQOsf8Yy-n6rR9jOT9pxgWVjRCUFaraUDb2KUXo9BD9ysQvTYlei9ZFtF6L1mvRhT_6SR3bFbg_-ldrAZoN0I15jJBs0WJBb6ay4a0P8E_4N_CQjQY</recordid><startdate>20160801</startdate><enddate>20160801</enddate><creator>Valldeoriola, Francesc</creator><creator>Grandas, Francisco</creator><creator>Santos-García, Diego</creator><creator>Regidor, Ignacio</creator><creator>Catalán, María José</creator><creator>Arbelo, José Matías</creator><creator>Puente, Víctor</creator><creator>Mir, Pablo</creator><creator>Parra, Juan Carlos</creator><general>Future Medicine Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>EHMNL</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope></search><sort><creationdate>20160801</creationdate><title>Long-term effectiveness of levodopa-carbidopa intestinal gel in 177 Spanish patients with advanced Parkinson's disease</title><author>Valldeoriola, Francesc ; Grandas, Francisco ; Santos-García, Diego ; Regidor, Ignacio ; Catalán, María José ; Arbelo, José Matías ; Puente, Víctor ; Mir, Pablo ; Parra, Juan Carlos</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c371t-8de77a445720c4f55519ee75036d5d7e61013cfbd1ca554b4c33de43a4b17b273</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>'off' time</topic><topic>Aged</topic><topic>Antiparkinson Agents - therapeutic use</topic><topic>Carbidopa - therapeutic use</topic><topic>Cross-Sectional Studies</topic><topic>Dopamine</topic><topic>Drug Combinations</topic><topic>dyskinesia</topic><topic>Enrollments</topic><topic>Family medical history</topic><topic>Female</topic><topic>Gels - therapeutic use</topic><topic>Humans</topic><topic>Intestines - physiology</topic><topic>Intravenous therapy</topic><topic>Levodopa - therapeutic use</topic><topic>levodopa-carbidopa intestinal gel</topic><topic>Logistics</topic><topic>Longitudinal Studies</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Motor Activity - drug effects</topic><topic>nonmotor symptoms</topic><topic>Ostomy</topic><topic>Parkinson Disease - drug therapy</topic><topic>Parkinson Disease - physiopathology</topic><topic>Parkinson's disease</topic><topic>Patients</topic><topic>Performance evaluation</topic><topic>Quality of life</topic><topic>Regression analysis</topic><topic>Retrospective Studies</topic><topic>Severity of Illness Index</topic><topic>Spain</topic><topic>Standard deviation</topic><topic>Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Valldeoriola, Francesc</creatorcontrib><creatorcontrib>Grandas, Francisco</creatorcontrib><creatorcontrib>Santos-García, Diego</creatorcontrib><creatorcontrib>Regidor, Ignacio</creatorcontrib><creatorcontrib>Catalán, María José</creatorcontrib><creatorcontrib>Arbelo, José Matías</creatorcontrib><creatorcontrib>Puente, Víctor</creatorcontrib><creatorcontrib>Mir, Pablo</creatorcontrib><creatorcontrib>Parra, Juan Carlos</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>UK & Ireland Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>Neurodegenerative disease management</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Valldeoriola, Francesc</au><au>Grandas, Francisco</au><au>Santos-García, Diego</au><au>Regidor, Ignacio</au><au>Catalán, María José</au><au>Arbelo, José Matías</au><au>Puente, Víctor</au><au>Mir, Pablo</au><au>Parra, Juan Carlos</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-term effectiveness of levodopa-carbidopa intestinal gel in 177 Spanish patients with advanced Parkinson's disease</atitle><jtitle>Neurodegenerative disease management</jtitle><addtitle>Neurodegener Dis Manag</addtitle><date>2016-08-01</date><risdate>2016</risdate><volume>6</volume><issue>4</issue><spage>289</spage><epage>298</epage><pages>289-298</pages><issn>1758-2024</issn><eissn>1758-2032</eissn><abstract>To assess long-term effectiveness and tolerability of levodopa-carbidopa intestinal gel (LCIG) in Spanish patients with advanced Parkinson's disease.
This was an observational, multicenter, cross-sectional, retrospective study.
Data of 177 patients were analyzed. LCIG treatment led to a reduction in the percentage of daily 'off' time (16.2 vs 47.6% before LCIG), an increase in the percentage of daily 'on' time without disabling dyskinesia (55.6 vs 21.6%). Most patients experienced improvements in freezing of gait, tremor, dizziness, fatigue or flat mood. Adverse events related to levodopa, gastrostomy and technical issues were reported in 36.2, 42.4 and 43.5% of patients, respectively.
This study confirms the long-term effectiveness and safety profile of LCIG in patients with advanced Parkinson's disease.</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>27440190</pmid><doi>10.2217/nmt-2016-0021</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1758-2024 |
| ispartof | Neurodegenerative disease management, 2016-08, Vol.6 (4), p.289-298 |
| issn | 1758-2024 1758-2032 |
| language | eng |
| recordid | cdi_proquest_journals_2341594412 |
| source | MEDLINE; PubMed Central |
| subjects | 'off' time Aged Antiparkinson Agents - therapeutic use Carbidopa - therapeutic use Cross-Sectional Studies Dopamine Drug Combinations dyskinesia Enrollments Family medical history Female Gels - therapeutic use Humans Intestines - physiology Intravenous therapy Levodopa - therapeutic use levodopa-carbidopa intestinal gel Logistics Longitudinal Studies Male Middle Aged Motor Activity - drug effects nonmotor symptoms Ostomy Parkinson Disease - drug therapy Parkinson Disease - physiopathology Parkinson's disease Patients Performance evaluation Quality of life Regression analysis Retrospective Studies Severity of Illness Index Spain Standard deviation Studies |
| title | Long-term effectiveness of levodopa-carbidopa intestinal gel in 177 Spanish patients with advanced Parkinson's disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T10%3A37%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-term%20effectiveness%20of%20levodopa-carbidopa%20intestinal%20gel%20in%20177%20Spanish%20patients%20with%20advanced%20Parkinson's%20disease&rft.jtitle=Neurodegenerative%20disease%20management&rft.au=Valldeoriola,%20Francesc&rft.date=2016-08-01&rft.volume=6&rft.issue=4&rft.spage=289&rft.epage=298&rft.pages=289-298&rft.issn=1758-2024&rft.eissn=1758-2032&rft_id=info:doi/10.2217/nmt-2016-0021&rft_dat=%3Cproquest_cross%3E2341594412%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2341594412&rft_id=info:pmid/27440190&rfr_iscdi=true |